Bioventus
BVS
80 hedge funds and large institutions have $175M invested in Bioventus in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 25 increasing their positions, 17 reducing their positions, and 12 closing their positions.
144% more call options, than puts
Call options by funds: $1.03M | Put options by funds: $421K
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
47% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 17
28% more capital inflows, than outflows
Capital inflows: $7.14M | Capital outflows: $5.58M
19% more funds holding
Funds holding: 67 → 80 (+13)
0.32% more ownership
Funds ownership: 52.55% → 52.87% (+0.32%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$724K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$613K |
| 3 |
Jane Street
New York
|
+$492K |
| 4 |
Laurion Capital Management
New York
|
+$468K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$344K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KLC
Kent Lake Capital
Reno,
Nevada
|
-$1.99M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$929K |
| 3 |
Millennium Management
New York
|
-$414K |
| 4 |
Bank of New York Mellon
New York
|
-$306K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$294K |
BVS Hedge Fund Activity: Q4 2023 in Review
80 of the 6,873 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q4 2023, worth a combined $175M — up 61% from $109M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BVS positions and 12 closed out — a net gain of 13 holders — while 25 added to existing stakes and 17 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $724K. The largest seller was Kent Lake Capital, cutting an estimated $1.99M.
- 80 institutional investors held Bioventus (BVS) as of Q4 2023, up from 67 in Q3 2023.
- Funds reported $175M of Bioventus stock for Q4 2023, up 61% quarter-over-quarter.
- 25 funds opened new Bioventus positions in Q4 2023 and 12 closed out, a net change of +13 holders.
- The largest Bioventus buyer in Q4 2023 was Morgan Stanley, an estimated $724K added.
- The largest Bioventus seller in Q4 2023 was Kent Lake Capital, an estimated $1.99M sold.
Based on aggregated 13F filings for Q4 2023.